Spots Global Cancer Trial Database for b acute lymphoblastic leukemia

Every month we try and update this database with for b acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia	NCT02877303	B Acute Lymphob... B Lymphoblastic...	Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul...	14 Years -	M.D. Anderson Cancer Center
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	NCT03504644	B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob...	Laboratory Biom... Venetoclax Vincristine Lip...	18 Years -	Eastern Cooperative Oncology Group
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)	NCT04557436	B Acute Lymphob...	PBLTT52CAR19	6 Months - 18 Years	Great Ormond Street Hospital for Children NHS Foundation Trust
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia	NCT03488225	Acute Lymphobla... B Acute Lymphob... B Acute Lymphob...	Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul...	16 Years -	M.D. Anderson Cancer Center
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia	NCT03488225	Acute Lymphobla... B Acute Lymphob... B Acute Lymphob...	Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul...	16 Years -	M.D. Anderson Cancer Center
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	NCT03241940	B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A...	1 Year - 30 Years	Stanford University
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	NCT02883049	B Acute Lymphob... B Acute Lymphob... Central Nervous... Testicular Leuk...	Clofarabine Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Etoposide Hydrocortisone ... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul...	1 Year - 31 Years	National Cancer Institute (NCI)
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).	NCT06078306	B Acute Lymphob... Ph-Negative ALL High Risk Acute...	Azacitidine Inj... Venetoclax CD19CD22 CAR-T	18 Years - 65 Years	The First Affiliated Hospital of Soochow University
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia	NCT02618109	B Acute Lymphob... Leukemia Relaps...	Collection of b...	1 Year - 18 Years	University Hospital, Angers
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	NCT02484430	B Acute Lymphob... B Acute Lymphob... B Acute Lymphob... Recurrent Adult... Refractory Adul... T Acute Lymphob...	Laboratory Biom... Pharmacological... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	NCT02883049	B Acute Lymphob... B Acute Lymphob... Central Nervous... Testicular Leuk...	Clofarabine Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Etoposide Hydrocortisone ... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul...	1 Year - 31 Years	National Cancer Institute (NCI)
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia	NCT03914625	B Acute Lymphob... B Lymphoblastic... Down Syndrome	Asparaginase Er... Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Leucovorin Calc... Mercaptopurine Mercaptopurine ... Methotrexate Pegaspargase Prednisolone Prednisone Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul...	365 Days - 31 Years	National Cancer Institute (NCI)
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia	NCT02877303	B Acute Lymphob... B Lymphoblastic...	Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul...	14 Years -	M.D. Anderson Cancer Center
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)	NCT06124157	B Acute Lymphob...	Biospecimen Col... Blinatumomab Bone Marrow Bio... Calaspargase Pe... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Doxorubicin Echocardiograph... Leucovorin Mercaptopurine Methotrexate Multigated Acqu... Pegaspargase Prednisolone Prednisone Radiation Thera... Thioguanine Vincristine	366 Days - 46 Years	National Cancer Institute (NCI)
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	NCT02828358	Acute Leukemia ... B Acute Lymphob... Mixed Phenotype...	Azacitidine Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Hydrocortisone ... Laboratory Biom... Leucovorin Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Pharmacological... Prednisolone Thioguanine Vincristine Vincristine Sul...	- 364 Days	National Cancer Institute (NCI)
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma	NCT05303792	B Acute Lymphob... B Lymphoblastic...	Cyclophosphamid... Vincristine Dexamethasone Inotuzumab Ozog... Methotrexate Cytarabine Methylprednisol... Rituximab Prednisone Mercaptopurine Doxorubicin	50 Years -	Alliance for Clinical Trials in Oncology
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	NCT03241940	B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A...	1 Year - 30 Years	Stanford University
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).	NCT06078306	B Acute Lymphob... Ph-Negative ALL High Risk Acute...	Azacitidine Inj... Venetoclax CD19CD22 CAR-T	18 Years - 65 Years	The First Affiliated Hospital of Soochow University
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission	NCT05707273	B Acute Lymphob...	Autologous Anti... Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Fludarabine Leukapheresis Questionnaire A...	55 Years -	City of Hope Medical Center
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia	NCT03914625	B Acute Lymphob... B Lymphoblastic... Down Syndrome	Asparaginase Er... Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Leucovorin Calc... Mercaptopurine Mercaptopurine ... Methotrexate Pegaspargase Prednisolone Prednisone Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul...	365 Days - 31 Years	National Cancer Institute (NCI)
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma	NCT05303792	B Acute Lymphob... B Lymphoblastic...	Cyclophosphamid... Vincristine Dexamethasone Inotuzumab Ozog... Methotrexate Cytarabine Methylprednisol... Rituximab Prednisone Mercaptopurine Doxorubicin	50 Years -	Alliance for Clinical Trials in Oncology
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia	NCT02968472	B Acute Lymphob...	prophylactic 4S...	6 Months -	The First People's Hospital of Yunnan
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia	NCT03150693	B Acute Lymphob...	Allopurinol Cytarabine Daunorubicin Hy... Vincristine Sul... Dexamethasone Pegylated L-Asp... Methotrexate Bone Marrow Asp... Cyclophosphamid... Mercaptopurine Rituximab Doxorubicin Thioguanine Inotuzumab Ozog... Laboratory Biom...	18 Years - 39 Years	Alliance for Clinical Trials in Oncology
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	NCT03504644	B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob...	Laboratory Biom... Venetoclax Vincristine Lip...	18 Years -	Eastern Cooperative Oncology Group
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease	NCT03441061	Acute Lymphobla... B Acute Lymphob... Recurrent B Acu...	Inotuzumab Ozog...	18 Years -	M.D. Anderson Cancer Center
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL	NCT05557110	B Acute Lymphob...	Blinatumomab	15 Years - 65 Years	The First Affiliated Hospital of Soochow University
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	NCT03959085	B Acute Lymphob... B Lymphoblastic... Central Nervous... Mixed Phenotype... Testicular Leuk...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bone Scan Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Leucovorin Calc... Magnetic Resona... Mercaptopurine Methotrexate Pegaspargase Positron Emissi... Prednisolone Questionnaire A... Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul...	1 Year - 25 Years	Children's Oncology Group
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)	NCT04557436	B Acute Lymphob...	PBLTT52CAR19	6 Months - 18 Years	Great Ormond Street Hospital for Children NHS Foundation Trust
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies	NCT03233854	B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... NKTR-255	18 Years -	Stanford University
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia	NCT05281809	B-Cell Lymphoma B Acute Lymphob... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Lymphoplasmacyt... Chronic Lymphoc... Transformed Lym...	Chimeric Antige...	18 Years - 79 Years	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia	NCT05157971	B Acute Lymphob... Ph-Like Acute L...	Cyclophosphamid... Cytarabine Daunorubicin Hy... Mercaptopurine Methotrexate Pegaspargase Prednisone Venetoclax Vincristine Sul...	18 Years - 54 Years	City of Hope Medical Center
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	NCT02828358	Acute Leukemia ... B Acute Lymphob... Mixed Phenotype...	Azacitidine Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Hydrocortisone ... Laboratory Biom... Leucovorin Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Pharmacological... Prednisolone Thioguanine Vincristine Vincristine Sul...	- 364 Days	National Cancer Institute (NCI)
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma	NCT05602194	B Acute Lymphob... B Acute Lymphob... B Acute Lymphob... Lymphoblastic L... Mixed Phenotype... T Acute Lymphob...	Biospecimen Col... Calaspargase Pe... Levocarnitine Pegaspargase Quality-of-Life...	15 Years - 40 Years	Children's Oncology Group
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	NCT03007147	Acute Lymphobla... B Acute Lymphob... Mixed Phenotype... T Acute Lymphob...	Allogeneic Hema... Calaspargase Pe... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Dexrazoxane Hyd... Doxorubicin Etoposide Filgrastim Ifosfamide Imatinib Mesyla... Laboratory Biom... Leucovorin Calc... Mercaptopurine Mercaptopurine Methotrexate Methylprednisol... Pegaspargase Prednisolone Questionnaire A... Therapeutic Hyd... Thioguanine Vincristine Sul...	1 Year - 21 Years	Children's Oncology Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: